Dr. Joseph M. Haggerty, M.D.
Hematology & Oncology (Hematology & Oncology Physician)
- Medicare participating
At a glance
- Medical school
- Virginia Commonwealth University, School of Medicine (1982)
- Years since graduation
- 44
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 490
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1982Medical school: Virginia Commonwealth University, School of Medicine
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Hematology & Oncology Physician primary
MD license D0032407
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Medicare patients and services
- Medicare patients, 2024
- 490
- Services billed
- 83,659
- Patients’ average age
- 77
| Service | Times | Patients |
|---|---|---|
| Injection, darbepoetin alfa, 1 microgram (non-esrd use) | 33,640 | 58 |
| Injection, ferric carboxymaltose, 1 mg | 21,750 | 24 |
| Injection, daratumumab, 10 mg and hyaluronidase-fihj | 13,320 | 19 |
| Injection, aprepitant, 1 mg | 7,540 | 31 |
| Injection, azacitidine, 1 mg | 7,200 | 14 |
| Injection, pembrolizumab, 1 mg | 6,800 | 18 |
| Injection, iron sucrose, 1 mg | 5,300 | 13 |
| Injection, denosumab, 1 mg | 3,540 | 18 |
| Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | 1,601 | 361 |
| Blood test, comprehensive group of blood chemicals | 1,515 | 347 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Eliquis (apixaban) Other prescribers in Rockville, MD | 41 |
| Acyclovir Other prescribers in Rockville, MD | 30 |
| Hydrocortisone Other prescribers in Rockville, MD | 23 |
| Anastrozole Other prescribers in Rockville, MD | 19 |
| Pomalyst (pomalidomide) | 19 |
| Hydroxyurea Other prescribers in Rockville, MD | 19 |
| Revlimid (lenalidomide) | 18 |
| Calquence (acalabrutinib maleate) | 17 |
| Gabapentin Other prescribers in Rockville, MD | 14 |
| Escitalopram Oxalate Other prescribers in Rockville, MD | 14 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 1 companies reported 1 payments worth $36.57 in total to this clinician.
| Array Biopharma Inc | $36.57 |
|---|
| Food and Beverage | $36.57 |
|---|
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 1 industry-funded study in 2025, from 1 company. The companies reported $1,031 in research payments for these studies, mostly to the institutions running them.
- A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Adv…
Eisai Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.